For instance histone deacetylase (HDAC) inhibitors have been shown to a) enhance expression of HLA class I on cancer cells [21], b) trigger cell death recruiting immune cells [22], c) trigger DNA damage of uveal melanoma cells resulting in activation of danger signals [23], d) block myeloid-derived suppressor cell (MDSC) activity [24], and e) enhance the expression of cancer antigens silenced by immunoediting [25]. Here, HDAC9 is linked to cancer.